-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA EXPANDS ANKTIVA® APPROVAL FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER TO COVER BOTH PAPILLARY AND CIS DISEASE

Reuters·10/14/2026 20:18:00

Please log in to view news